



**THE FOUNDATION
FOR SECURE
MARKETS®**

#54893

Date: July 18, 2024

Subject: TARO Options - Expiration Pricing Consideration

TARO (adjusted Taro Pharmaceutical Industries Ltd. options) will be subject to special pricing consideration in expiration processing on July 19, 2024. The pricing consideration is due to the undetermined final net cash amount included in the option deliverable of TARO as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

TARO

TARO options are adjusted Taro Pharmaceutical Industries Ltd. options, adjusted June 24, 2024 (see OCC Information Memo #54779). The deliverable of TARO options is:

NEW DELIVERABLE

PER CONTRACT: \$4,300.00 Cash (\$43.00 x 100), less withholdings, if any

As of July 18, 2024, the TARO Exchange Agent has not determined the final net cash merger consideration applicable in the merger.

For purposes of calculating a TARO price for use in expiration processing, OCC will use the following formula:

$$\text{TARO} = 43.00$$

This formula includes an estimate for the value of the final net cash merger consideration of TARO shares based on the merger consideration amount before additional fees, if any, are determined, and not the actual net cash amount per share applicable in the merger.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.